Asset
Tuxobertinib
Black Diamond Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04209465 | phase1 | terminated | 2019-12-19 | 2022-09-02 | Black Diamond Therapeutics, Inc. | A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors. |
FDA applications (0)
This company has no applications containing this asset.